Potential voriconazole associated posterior reversible leukoencephalopathy in children with malignancies: Report of two cases

Abstract

Introduction

The fungal infection has become severe morbidity amongst patients with malignancy. Voriconazole, a new generation of triazole, has shown excellent results in treating invasive fungal infections.

Case report

Herein, we report two cases of posterior reversible encephalopathy syndrome (PRES), which induced after voriconazole exposure.

Management and outcome: Magnetic resonance imaging, and the serum level of voriconazole were investigated in both patients to assess toxicity. The role of methotrexate, as one of the possible causes of PRES, is weakened significantly through precise assessing diffusion-weighted images on magnetic resonance imaging.

Discussion

These unique cases emphasize that voriconazole can induce PRES even at therapeutic levels. Therefore, in the case of neurotoxicity, PRES must be considered, and voriconazole should discontinue. The prognosis seemed promising when voriconazole stopped immediately after clinical suspicion.

Keywords

Voriconazole posterior reversible encephalopathy syndrome invasive fungal infections malignancy

Get full access to this article

View all access options for this article.

References

Sun

, et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. Tumour Biol 2015; 36: 757–767.

Gupta

, et al. Comparative evaluation of pan-fungal real-time PCR, galactomannan and (1-3)-beta-D-glucan assay for invasive fungal infection in paediatric cancer patients. Mycoses 2017; 60: 234–240.

De Pauw

, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821.

Luong

M-L

, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother 2016; 71: 1786–1799.

Pascual

, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–211.

Boyd

, et al. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39: 1241–1244.

Agarwal

Kapur

and Altinok

Childhood posterior reversible encephalopathy syndrome: magnetic resonance imaging findings with emphasis on increased leptomeningeal FLAIR signal.

Neuroradiol J 2015; 28: 638–643.

Fugate

Rabinstein

AA.

Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions.

Lancet Neurol 2015; 14: 914–925.

Jenny

and Castaldo

Posterior reversible encephalopathy syndrome: clinicoradiological spectrum and therapeutic strategies.

Hosp Pract 2012; 40: 202–213.

10.

Pilato

Distefano

and Calandrelli

Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome: clinical and radiological considerations. Front Neurol 2020; 11: 34.

11.

Sudulagunta

, et al. Posterior reversible encephalopathy syndrome (PRES). Oxford Med Case Rep 2017; 2017: omx011.

12.

Hamid

, et al. Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer. J Commun Hosp Intern Med Perspect 2018; 8: 130–133.

13.

Pula

Eggenberger

Posterior reversible encephalopathy syndrome. Curr Opin Ophthalmol 2008; 19: 479–484.

14.

Mellinghoff

, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 2018; 97: 197–207.

15.

Michael Neely

DN.

Voriconazole. 6. Adverse reactions and toxicity. In: M

Lindsay Grayson

, et al. (eds) Kucers' the use of antibiotics seventh edition: a clinical review of antibacterial, antifungal and antiviral drugs. Boca Raton, FL: CRC Press, 2018, p.2832.

16.

Lindsay Grayson

, et al. Those requiring altered dosages (4d), patients with impaired hepatic function. In: DN

Michael Neely

(ed.) Kucers' the use of antibiotics seventh edition: a clinical review of antibacterial, antifungal and antiviral drugs Boca Raton, FL: CRC Press, 2018, p. 2827.

17.

Lindsay Grayson

, et al. Voriconazole. 5b. Drug distribution. In: DN

Michael Neely

(ed.) Kucers' the use of antibiotics seventh edition: a clinical review of antibacterial, antifungal and antiviral drugs Boca Raton, FL: CRC Press, 2018, p. 2828.

18.

Lindsay Grayson

, et al. Newborn infants and children (4b). In: DN

Michael Neely

(ed.) Kucers' the use of antibiotics seventh edition: a clinical review of antibacterial, antifungal and antiviral drugs. Boca Raton, FL: CRC Press, 2018, p. 2826.

19.

Chu

, et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis 2013; 13: 105.

20.

Pascual

, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–211.

21.

Levêque

, et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 27: 274–284.

22.

Theuretzbacher

, Ihle

and Derendorf

Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet2006; 45: 649–663.

23.

, et al. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents 2017; 49: 403–409.

24.

Harnicar

Adel

and Jurcic

Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.

J Oncol Pharm Pract 2009; 15: 175–182.

25.

Porter

, Carver

and Albano

EA.

Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.

Pediatr Blood Cancer 2009; 52: 298–300.

26.

Miese

, et al. Magnetization transfer imaging provides no evidence of demyelination in methotrexate-induced encephalopathy. AmJ Neuroradiol 2011; 32: E110–E112.

27.

Tan

, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235–243.

28.

Brown

Van Manen

RJC.

Voriconazole associated leukoencephalopathy: a review of the FDA AERS database. In: 51st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, 2011, pp. 17–20.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB

0.11 MB

0.34 MB